|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ERF |
Gene summary for ERF |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ERF | Gene ID | 2077 |
| Gene name | ETS2 repressor factor | |
| Gene Alias | CHYTS | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P50548 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2077 | ERF | S43 | Human | Liver | Cirrhotic | 2.30e-06 | -2.22e-01 | -0.0187 |
| 2077 | ERF | HCC1_Meng | Human | Liver | HCC | 3.60e-53 | -5.39e-02 | 0.0246 |
| 2077 | ERF | HCC2_Meng | Human | Liver | HCC | 3.91e-11 | -8.56e-02 | 0.0107 |
| 2077 | ERF | cirrhotic1 | Human | Liver | Cirrhotic | 7.07e-06 | 1.07e-01 | 0.0202 |
| 2077 | ERF | cirrhotic2 | Human | Liver | Cirrhotic | 6.28e-04 | 3.11e-02 | 0.0201 |
| 2077 | ERF | Pt13.b | Human | Liver | HCC | 7.22e-05 | -1.65e-02 | 0.0251 |
| 2077 | ERF | S014 | Human | Liver | HCC | 3.88e-15 | 7.21e-01 | 0.2254 |
| 2077 | ERF | S015 | Human | Liver | HCC | 1.11e-15 | 8.51e-01 | 0.2375 |
| 2077 | ERF | S016 | Human | Liver | HCC | 9.70e-12 | 5.70e-01 | 0.2243 |
| 2077 | ERF | S028 | Human | Liver | HCC | 1.06e-04 | 3.79e-01 | 0.2503 |
| 2077 | ERF | C04 | Human | Oral cavity | OSCC | 1.93e-08 | 8.16e-01 | 0.2633 |
| 2077 | ERF | C21 | Human | Oral cavity | OSCC | 8.56e-06 | 3.56e-01 | 0.2678 |
| 2077 | ERF | C30 | Human | Oral cavity | OSCC | 1.09e-32 | 1.48e+00 | 0.3055 |
| 2077 | ERF | C38 | Human | Oral cavity | OSCC | 5.00e-06 | 1.14e+00 | 0.172 |
| 2077 | ERF | C43 | Human | Oral cavity | OSCC | 3.70e-18 | 4.47e-01 | 0.1704 |
| 2077 | ERF | C51 | Human | Oral cavity | OSCC | 5.34e-04 | 4.64e-01 | 0.2674 |
| 2077 | ERF | C06 | Human | Oral cavity | OSCC | 2.38e-04 | 1.28e+00 | 0.2699 |
| 2077 | ERF | C08 | Human | Oral cavity | OSCC | 3.61e-25 | 6.17e-01 | 0.1919 |
| 2077 | ERF | C09 | Human | Oral cavity | OSCC | 2.70e-24 | 1.18e+00 | 0.1431 |
| 2077 | ERF | LN46 | Human | Oral cavity | OSCC | 9.67e-06 | 6.54e-01 | 0.1666 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006605110 | Oral cavity | LP | protein targeting | 156/4623 | 314/18723 | 5.43e-22 | 1.62e-19 | 156 |
| GO:003447014 | Oral cavity | LP | ncRNA processing | 184/4623 | 395/18723 | 1.20e-21 | 3.12e-19 | 184 |
| GO:003466011 | Oral cavity | LP | ncRNA metabolic process | 205/4623 | 485/18723 | 6.46e-18 | 1.09e-15 | 205 |
| GO:000640319 | Oral cavity | LP | RNA localization | 105/4623 | 201/18723 | 3.34e-17 | 5.36e-15 | 105 |
| GO:0042255110 | Oral cavity | LP | ribosome assembly | 44/4623 | 61/18723 | 8.20e-15 | 1.05e-12 | 44 |
| GO:000683919 | Oral cavity | LP | mitochondrial transport | 119/4623 | 254/18723 | 1.06e-14 | 1.33e-12 | 119 |
| GO:007058519 | Oral cavity | LP | protein localization to mitochondrion | 70/4623 | 125/18723 | 6.73e-14 | 7.02e-12 | 70 |
| GO:007265519 | Oral cavity | LP | establishment of protein localization to mitochondrion | 68/4623 | 120/18723 | 6.98e-14 | 7.16e-12 | 68 |
| GO:0031647110 | Oral cavity | LP | regulation of protein stability | 132/4623 | 298/18723 | 8.16e-14 | 7.99e-12 | 132 |
| GO:000662619 | Oral cavity | LP | protein targeting to mitochondrion | 58/4623 | 100/18723 | 1.23e-12 | 1.00e-10 | 58 |
| GO:004312316 | Oral cavity | LP | positive regulation of I-kappaB kinase/NF-kappaB signaling | 88/4623 | 186/18723 | 1.58e-11 | 1.13e-09 | 88 |
| GO:005123615 | Oral cavity | LP | establishment of RNA localization | 79/4623 | 166/18723 | 1.18e-10 | 6.81e-09 | 79 |
| GO:0043254110 | Oral cavity | LP | regulation of protein-containing complex assembly | 163/4623 | 428/18723 | 3.72e-10 | 1.92e-08 | 163 |
| GO:004312219 | Oral cavity | LP | regulation of I-kappaB kinase/NF-kappaB signaling | 103/4623 | 249/18723 | 4.48e-09 | 1.90e-07 | 103 |
| GO:0031334110 | Oral cavity | LP | positive regulation of protein-containing complex assembly | 99/4623 | 237/18723 | 4.83e-09 | 2.00e-07 | 99 |
| GO:005165615 | Oral cavity | LP | establishment of organelle localization | 147/4623 | 390/18723 | 6.01e-09 | 2.46e-07 | 147 |
| GO:014005312 | Oral cavity | LP | mitochondrial gene expression | 53/4623 | 108/18723 | 3.54e-08 | 1.27e-06 | 53 |
| GO:0051348110 | Oral cavity | LP | negative regulation of transferase activity | 106/4623 | 268/18723 | 4.60e-08 | 1.61e-06 | 106 |
| GO:000724917 | Oral cavity | LP | I-kappaB kinase/NF-kappaB signaling | 110/4623 | 281/18723 | 4.94e-08 | 1.70e-06 | 110 |
| GO:000072317 | Oral cavity | LP | telomere maintenance | 59/4623 | 131/18723 | 2.88e-07 | 8.56e-06 | 59 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ERF | CD8TRM | Cervix | CC | TRIM24,LINC00641,EVA1B, etc. | 1.62e-01 |  |
| ERF | CD8TRM | Cervix | N_HPV | TRIM24,LINC00641,EVA1B, etc. | 2.98e-01 |  |
| ERF | QUIE | Esophagus | ESCC | IER5,NUMBL,SERTAD1, etc. | 7.95e-02 |  |
| ERF | STM | Esophagus | HGIN | IER5,NUMBL,SERTAD1, etc. | 2.50e-01 |  |
| ERF | STM | Liver | Healthy | PMAIP1,FOXA2,RQCD1, etc. | 6.73e-01 |  |
| ERF | MSC.MVA | Liver | Cirrhotic | CTU1,ZNF781,ABCF2, etc. | 1.27e-01 |  |
| ERF | MVA | Liver | Healthy | CTU1,ZNF781,ABCF2, etc. | 5.47e-02 | |
| ERF | MSC.MVA | Liver | Healthy | CTU1,ZNF781,ABCF2, etc. | 2.64e-02 | |
| ERF | TFH | Lung | IAC | IL15RA,AC007952.4,FRYL, etc. | 1.69e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ERF | SNV | Missense_Mutation | novel | c.260N>G | p.Tyr87Cys | p.Y87C | P50548 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-4H-AAAK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | CR |
| ERF | SNV | Missense_Mutation | c.1541N>A | p.Arg514His | p.R514H | P50548 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.511) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ERF | SNV | Missense_Mutation | rs368169058 | c.427N>T | p.Arg143Cys | p.R143C | P50548 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-W8-A86G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| ERF | SNV | Missense_Mutation | c.610N>A | p.Pro204Thr | p.P204T | P50548 | protein_coding | tolerated(0.53) | benign(0.362) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| ERF | SNV | Missense_Mutation | c.1471N>A | p.Asp491Asn | p.D491N | P50548 | protein_coding | deleterious(0) | possibly_damaging(0.746) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ERF | SNV | Missense_Mutation | c.1513N>C | p.Glu505Gln | p.E505Q | P50548 | protein_coding | tolerated_low_confidence(0.79) | benign(0.014) | TCGA-EK-A2RB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ERF | SNV | Missense_Mutation | novel | c.1519G>A | p.Glu507Lys | p.E507K | P50548 | protein_coding | deleterious_low_confidence(0) | benign(0.007) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ERF | SNV | Missense_Mutation | c.1628N>C | p.Leu543Pro | p.L543P | P50548 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ERF | SNV | Missense_Mutation | rs767080643 | c.616N>A | p.Ala206Thr | p.A206T | P50548 | protein_coding | tolerated(0.43) | benign(0.082) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ERF | SNV | Missense_Mutation | novel | c.502N>C | p.Ser168Pro | p.S168P | P50548 | protein_coding | tolerated(0.09) | possibly_damaging(0.763) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |